http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2011108471-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 |
| filingDate | 2011-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2011108471-A1 |
| titleOfInvention | Virus inhibitor |
| abstract | A virus inhibitor comprising a polyvalent sialosugar chain or asialoglycan glycoside represented by the following general formula as an active ingredient (in the above formula (I), W 1 and W 2 are hydroxyl groups or N-acetylneuraminic acid residues, respectively) X represents a hydroxyl group or an acetylamino group, Y represents a divalent linking group represented by the general formula (Y-1) or (Y-2), m represents an integer of 0 or 1; N represents an integer of 2 to 4, and Z represents a single bond or a divalent to tetravalent linking group, provided that both W 1 and W 2 do not become N-acetylneuraminic acid residues. In formulas (Y-1) and (Y-2), L 1 represents a divalent linking group consisting of at least one selected from the group consisting of a hydrocarbon group, a hydrocarbon group containing an amide bond, and an ether group. represents, L 2 is selected from the group consisting of oxyalkylene group, an amide group and an alkylene group It represents a divalent linking group formed from at least one. |
| priorityDate | 2010-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 232.